Lyell Immunopharma director gets stock option grant
Lyell Immunopharma director Elizabeth G. Nabel received a grant of stock options covering 9,250 shares of common stock.
Rhea-AI Filing Summary
Lyell Immunopharma director Elizabeth G. Nabel received a grant of stock options covering 9,250 shares of common stock. The options have an exercise price of $13.22 per share and were awarded as a compensation grant, not an open-market purchase or sale.
The options vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before that date if her board service ends at that meeting), or the first anniversary of June 10, 2026, provided she continues serving as a director. The options expire on June 9, 2036, and following this grant she holds options to acquire 9,250 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 9,250 shares
Grant/Award
1 txn
Insider
NABEL ELIZABETH G
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (right to buy) | 9,250 | $0.00 | $0.00 |
Holdings After Transaction:
Option (right to buy) — 9,250 contracts (Direct)
Footnotes (1)
- F1. The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Key Figures
Options granted: 9,250 options
Exercise price: $13.22 per share
Underlying shares: 9,250 shares
+3 more
6 metrics
Options granted
9,250 options
Grant to director Elizabeth G. Nabel
Exercise price
$13.22 per share
Option grant exercise price
Underlying shares
9,250 shares
Common stock underlying the options
Options after grant
9,250 options
Total derivative holdings following transaction
Grant date reference
June 10, 2026
Date used for vesting conditions
Expiration date
June 9, 2036
Option expiration
Key Terms
Option (right to buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more
5 terms
Option (right to buy) financial
"security_title: Option (right to buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
exercise price financial
"conversion_or_exercise_price: 13.2200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-09T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"The option shares shall vest on the earlier of (a) the date of the next annual meeting..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Lyell Immunopharma (LYEL) director Elizabeth Nabel report in this Form 4?
Director Elizabeth G. Nabel reported receiving a grant of options for 9,250 shares of Lyell Immunopharma common stock. These options were granted as compensation, not purchased in the open market, and give her the right to buy shares at a fixed exercise price.
How many Lyell Immunopharma (LYEL) options did Elizabeth Nabel receive and at what exercise price?
Elizabeth G. Nabel received options covering 9,250 shares of Lyell Immunopharma common stock. The options carry an exercise price of $13.22 per share, meaning she can buy the underlying shares at that price once the options have vested.
When do Elizabeth Nabel’s Lyell Immunopharma (LYEL) stock options vest?
The option shares vest on the earlier of the next annual stockholder meeting after June 10, 2026, or the first anniversary of June 10, 2026. Vesting is contingent on her providing continuous service as a director through the applicable vesting date.
When do the Lyell Immunopharma (LYEL) options granted to Elizabeth Nabel expire?
The options granted to Elizabeth G. Nabel expire on June 9, 2036. After that expiration date, any unexercised options will lapse, and she will no longer have the right to purchase Lyell Immunopharma common stock under this particular grant.
Is Elizabeth Nabel’s Lyell Immunopharma (LYEL) Form 4 transaction a stock purchase or sale?
The Form 4 reports an option grant, not a purchase or sale of common shares. It is classified as a grant, award, or other acquisition of derivative securities, providing potential future ownership if the options are exercised after vesting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
